<prompt> Antiplatelet drug acting via purinergic receptors, not largely impacted by CYP2C19 polymorphism is:TiclopidinePrasugrelClopidogrelAbciximab  <response>: Ref. KDT. Page. 629Prasugrel is a prodrug , similar to ClopidogrelThienopyridine drug classIrreversible antagonist of P2Y12 ADP receptorsRapidly absorbed, completely activated exerts more consistent platelet inhibition. No interaction with CYP2C19 polymorphismStrong anti-platelet activityBleeding complications are more serious and frequent.Contraindicated in patients with history of ischemic strokes and TIAs 